Cerevel Financial Statements From 2010 to 2024

CERE Stock  USD 41.90  0.09  0.21%   
Cerevel Therapeutics financial statements provide useful quarterly and yearly information to potential Cerevel Therapeutics Holdings investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Cerevel Therapeutics financial statements helps investors assess Cerevel Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Cerevel Therapeutics' valuation are summarized below:
Market Capitalization
7.6 B
Earnings Share
(2.67)
There are over one hundred nineteen available fundamental signals for Cerevel Therapeutics Holdings, which can be analyzed over time and compared to other ratios. Investors should ensure to validate all of Cerevel Therapeutics' prevailing performance against the performance from 2010 to 2024 to make sure the company is sustainable down the road. The current year's Market Cap is expected to grow to about 4.5 B. The current year's Enterprise Value is expected to grow to about 4.7 B

Cerevel Therapeutics Total Revenue

0.0

Check Cerevel Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cerevel main balance sheet or income statement drivers, such as Depreciation And Amortization of 8.1 M, Interest Expense of 12.6 M or Selling General Administrative of 107 K, as well as many exotic indicators such as Price To Sales Ratio of 39.33, Dividend Yield of 0.0 or PTB Ratio of 9.22. Cerevel financial statements analysis is a perfect complement when working with Cerevel Therapeutics Valuation or Volatility modules.
  
This module can also supplement Cerevel Therapeutics' financial leverage analysis and stock options assessment as well as various Cerevel Therapeutics Technical models . Check out the analysis of Cerevel Therapeutics Correlation against competitors.

Cerevel Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets1.3 B1.2 B360.1 M
Slightly volatile
Short and Long Term Debt Total504.8 M480.8 M102.8 M
Slightly volatile
Other Current Liabilities80.8 M76.9 M14.6 M
Slightly volatile
Total Current Liabilities96.8 M92.2 M25.9 M
Slightly volatile
Total Stockholder Equity707.4 M673.7 M228.6 M
Slightly volatile
Property Plant And Equipment Net29 M45.8 M24 M
Slightly volatile
Current Deferred Revenue34.3 M32.7 M13.3 M
Slightly volatile
Accounts Payable6.6 M11.9 M5.3 M
Slightly volatile
CashB991 M209.8 M
Slightly volatile
Cash And Short Term InvestmentsB991 M294.8 M
Slightly volatile
Net Receivables5.6 M5.3 M1.4 M
Slightly volatile
Common Stock Total Equity13.7 K14.4 K212.8 K
Slightly volatile
Common Stock Shares Outstanding88.2 M162.1 M81.3 M
Slightly volatile
Liabilities And Stockholders Equity1.3 B1.2 B360.1 M
Slightly volatile
Non Current Liabilities Total501.2 M477.4 M108.5 M
Slightly volatile
Other Current Assets11.2 M10.7 M4.2 M
Slightly volatile
Other Stockholder Equity2.2 B2.1 B664.8 M
Slightly volatile
Total Liabilities598 M569.6 M136.2 M
Slightly volatile
Property Plant And Equipment Gross30.6 M58.3 M25 M
Slightly volatile
Total Current Assets1.1 BB303.9 M
Slightly volatile
Short Term Debt2.5 M3.4 M2.1 M
Slightly volatile
Common Stock17.1 K18 K213.3 K
Slightly volatile
Other Liabilities40.5 M38.6 M13.1 M
Slightly volatile
Property Plant Equipment34.2 M31.6 M14.8 M
Slightly volatile
Capital Lease Obligations35.9 M31.2 M30.3 M
Slightly volatile
Deferred Long Term Liabilities244.5 K257.4 K1.1 M
Slightly volatile
Net Invested Capital640 MB283.3 M
Slightly volatile
Capital Stock15 K18 K9.1 K
Slightly volatile
Non Current Liabilities Other59.5 M112.2 M23.2 M
Slightly volatile
Net Working Capital597.6 M914.8 M264.3 M
Slightly volatile
Capital Surpluse1.3 B1.7 B945.9 M
Slightly volatile
Long Term Debt370.1 M337.4 M337.9 M
Slightly volatile
Long Term Debt Total268.4 M301.9 M328.8 M
Slightly volatile

Cerevel Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization8.1 M5.6 M14.6 M
Pretty Stable
Selling General Administrative107 K112.6 K27.2 M
Slightly volatile
Other Operating Expenses469.6 M447.3 M147 M
Slightly volatile
Research Development351.4 M334.6 M102 M
Slightly volatile
Cost Of Revenue4.2 M5.6 M2.7 M
Very volatile
Total Operating Expenses463.7 M441.6 M144.8 M
Slightly volatile
Net Interest Income28.2 M26.8 M5.4 M
Slightly volatile
Interest Income46.1 M43.9 M7.7 M
Slightly volatile
Reconciled DepreciationM5.6 M1.2 M
Slightly volatile

Cerevel Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation72.9 M69.4 M17.5 M
Slightly volatile
Begin Period Cash Flow936.6 M892 M181.1 M
Slightly volatile
Depreciation5.9 M5.6 MM
Slightly volatile
Capital Expenditures3.6 M3.8 M12 M
Pretty Stable
End Period Cash FlowB991 M213.9 M
Slightly volatile
Change To Netincome33.4 M35.2 M271.8 M
Slightly volatile
Change To Liabilities36.3 M34.6 M10.9 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio39.3356.0654.7954
Slightly volatile
PTB Ratio9.2210.198512.8998
Very volatile
Days Sales Outstanding50.4469.6969.584
Slightly volatile
Book Value Per Share2.374.15752.3889
Pretty Stable
Invested Capital0.710.67230.3596
Slightly volatile
Stock Based Compensation To Revenue0.620.750.7655
Pretty Stable
PB Ratio9.2210.198512.8998
Very volatile
EV To Sales37.6854.8453.0737
Slightly volatile
Payables Turnover0.730.47430.4544
Slightly volatile
Sales General And Administrative To Revenue3.425.285.0059
Slightly volatile
Research And Ddevelopement To Revenue3.233.23.6415
Slightly volatile
Cash Per Share10.149.663.3686
Slightly volatile
Capex To Operating Cash Flow0.01060.01110.035
Very volatile
Days Payables Outstanding9507702.3 K
Pretty Stable
Income Quality0.860.79080.7319
Very volatile
Current Ratio7.2310.92378.0706
Slightly volatile
Receivables Turnover6.525.425.3589
Slightly volatile
Graham Number8.8215.80669.1558
Very volatile
Shareholders Equity Per Share2.374.15752.3889
Pretty Stable
Debt To Equity0.710.67230.3596
Slightly volatile
Graham Net Net6.486.172.3311
Slightly volatile
Revenue Per Share0.310.220.236
Slightly volatile
Interest Debt Per Share3.02.86050.7479
Slightly volatile
Debt To Assets0.350.36430.5218
Pretty Stable
Price Book Value Ratio9.2210.198512.8998
Very volatile
Days Of Payables Outstanding9507702.3 K
Pretty Stable
Ebt Per Ebit0.840.96661.1647
Very volatile
Company Equity Multiplier1.941.84541.2426
Slightly volatile
Long Term Debt To Capitalization0.420.40020.2244
Slightly volatile
Total Debt To Capitalization0.420.4020.2316
Slightly volatile
Debt Equity Ratio0.710.67230.3596
Slightly volatile
Quick Ratio17.8917.04038.8867
Slightly volatile
Dividend Paid And Capex Coverage Ratio94.3889.8950.4595
Slightly volatile
Net Income Per E B T1.11.00121.0061
Slightly volatile
Cash Ratio11.2910.75045.2881
Slightly volatile
Days Of Sales Outstanding50.4469.6969.584
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.141.01111.0437
Pretty Stable
Price To Book Ratio9.2210.198512.8998
Very volatile
Fixed Asset Turnover1.011.951.748
Slightly volatile
Capital Expenditure Coverage Ratio94.3889.8950.4595
Slightly volatile
Debt Ratio0.350.36430.5218
Pretty Stable
Price Sales Ratio39.3356.0654.7954
Slightly volatile
Asset Turnover1.91.811.5867
Slightly volatile
Price Fair Value9.2210.198512.8998
Very volatile
Operating Cycle10889.0492.6259
Slightly volatile

Cerevel Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap4.5 B4.3 B1.8 B
Slightly volatile
Enterprise Value4.7 B4.5 B1.8 B
Slightly volatile

Cerevel Fundamental Market Drivers

Cash And Short Term Investments991 M

Cerevel Upcoming Events

28th of February 2024
Upcoming Quarterly Report
View
1st of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
28th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Cerevel Therapeutics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Cerevel Therapeutics income statement, its balance sheet, and the statement of cash flows. Cerevel Therapeutics investors use historical funamental indicators, such as Cerevel Therapeutics's revenue or net income, to determine how well the company is positioned to perform in the future. Although Cerevel Therapeutics investors may use each financial statement separately, they are all related. The changes in Cerevel Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Cerevel Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Cerevel Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Cerevel Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue32.7 M34.3 M
Total Revenue 0.00  0.00 
Cost Of Revenue5.6 M4.2 M
Stock Based Compensation To Revenue 0.75  0.62 
Sales General And Administrative To Revenue 5.28  3.42 
Research And Ddevelopement To Revenue 3.20  3.23 
Capex To Revenue(0.14)(0.13)
Revenue Per Share 0.22  0.31 
Ebit Per Revenue(11.91)(12.51)

Pair Trading with Cerevel Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cerevel Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cerevel Therapeutics will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Cerevel Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cerevel Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cerevel Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cerevel Therapeutics Holdings to buy it.
The correlation of Cerevel Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cerevel Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cerevel Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cerevel Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Cerevel Therapeutics is a strong investment it is important to analyze Cerevel Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cerevel Therapeutics' future performance. For an informed investment choice regarding Cerevel Stock, refer to the following important reports:
Check out the analysis of Cerevel Therapeutics Correlation against competitors.
You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.

Complementary Tools for Cerevel Stock analysis

When running Cerevel Therapeutics' price analysis, check to measure Cerevel Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cerevel Therapeutics is operating at the current time. Most of Cerevel Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cerevel Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cerevel Therapeutics' price. Additionally, you may evaluate how the addition of Cerevel Therapeutics to your portfolios can decrease your overall portfolio volatility.
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Commodity Directory
Find actively traded commodities issued by global exchanges
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Is Cerevel Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cerevel Therapeutics. If investors know Cerevel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cerevel Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.67)
Return On Assets
(0.25)
Return On Equity
(0.72)
The market value of Cerevel Therapeutics is measured differently than its book value, which is the value of Cerevel that is recorded on the company's balance sheet. Investors also form their own opinion of Cerevel Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cerevel Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cerevel Therapeutics' market value can be influenced by many factors that don't directly affect Cerevel Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cerevel Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cerevel Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cerevel Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.